Editas Medicine, Inc. 8-K

What Happened

• Editas Medicine filed a Form 8-K on March 27, 2026 to disclose a press release reporting that on March 26, 2026 the U.S. Patent and Trademark Office (USPTO) reaffirmed the Patent Trial and Appeal Board’s (PTAB’s) prior decision in favor of the Broad Institute in the patent interference over CRISPR/Cas9 editing in human cells.
• The interference involved patents asserted by the University of California, the University of Vienna and Emmanuelle Charpentier (collectively “CVC”) versus the Broad Institute, MIT and Harvard. The matter was on remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) after the CAFC’s May 2025 decision that affirmed-in-part and vacated-in-part the PTAB ruling. CVC retains the right to appeal to the CAFC. Editas furnished the company press release as Exhibit 99.1 to the 8-K.

Key Details

• Filing: Form 8-K filed March 27, 2026 (Items 7.01 and 8.01); press release dated March 27, 2026 furnished as Exhibit 99.1.
• Decision date: USPTO reaffirmation issued March 26, 2026.
• Parties: Interference between CVC (UC, Vienna, Emmanuelle Charpentier) and Broad Institute/MIT/Harvard.
• Procedural history: Matter remanded from CAFC after its May 2025 decision; CVC may appeal to the CAFC.

Why It Matters

• The USPTO’s reaffirmation confirms the PTAB outcome in a high-profile patent dispute over CRISPR/Cas9 editing in human cells. Patent outcomes in this case shape the intellectual property landscape for CRISPR technology, which can affect licensing, collaborations and competitive positions among gene-editing companies.
• Editas’ disclosure informs investors of a material industry legal development; the company did not disclose any direct financial impact or changes to its operations in the filing.